SLIT2-IT1

Across TCGA pan-cancer cohorts, SLIT2-IT1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLIT2-IT1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLIT2-IT1 RNA is repressed in tumor relative to normal tissue. In most cancer types SLIT2-IT1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and COAD are the cancer types where SLIT2-IT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLIT2-IT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.120	.001	5	view →
KIRC	All	All	−0.029	.006	5	view →
COAD	Male	All	−0.127	<.001	4	view →
BLCA	All	All	−0.157	.043	2	view →
KICH	All	IV	+0.067	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLIT2-IT1–THCA

Open the THCA breakdown →